Last updated on March 2019

ABI-009 an mTOR Inhibitor for Patients With Severe Pulmonary Arterial Hypertension


Brief description of study

mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

Clinical Study Identifier: NCT02587325

Find a site near you

Start Over

Inova Fairfax Hospital

Falls Church, VA United States
1.86miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.